The Global Anti-Addiction Market, 2008-2023

Table of Contents

1. Executive Summary

2. Introduction: Worldwide Prevalence and Treatment of Addiction

• 2.1 The Physiology and Psychology of Addiction
  • 2.1.1 Definition of Addiction
  • 2.1.2 Addiction is Caused by Physical Dependence
  • 2.1.3 Psychological Dependence
• 2.2 Prevalence of Addiction
• 2.3 Addiction Therapy
  • 2.3.1 Behavioural Therapy
  • 2.3.2 Addiction Treatment with Drugs
  • 2.3.3 Off-Label Drug Prescribing for Addiction Therapy
• 2.4 Smoking Cessation Products
  • 2.4.1 Nicotine Replacement Therapy (NRT)
  • 2.4.2 Nicotine Replacement Therapy Products (Johnson & Johnson)
  • 2.4.3 Nicotine Replacement Therapy Products (GSK)
  • 2.4.4 Nicotine Replacement Therapy Products (Novartis)
  • 2.4.5 Chantix/Champix (Pfizer)
  • 2.4.6 Zyban (GSK/Biovail)
• 2.5 Obesity Drugs
  • 2.5.1 Xenical (Roche)
  • 2.5.2 Reductil/Meridia (Abbott Laboratories)
  • 2.5.3 Alli (GSK)
  • 2.5.4 Acomplia (Sanofi-Aventis)
  • 2.5.5 Other Obesity Drugs
• 2.6 Drugs Used In Opioid Dependence
  • 2.6.1 Suboxone/Subutex (Reckitt Benckiser/ Schering-Plough)
  • 2.6.2 Methadone
  • 2.6.3 Naltrexone
  • 2.6.4 Other Drugs Used in Opioid Addiction Treatment
• 2.7 Alcohol Dependency Drugs
  • 2.7.1 Campral/Aotal (Merck KGaA/Forest)
  • 2.7.2 Antabuse (Barr)
  • 2.7.3 Naltrexone
  • 2.7.4 Vivitrol (Alkermes/Cephalon/Johnson & Johnson)
  • 2.7.5 Revia (Barr/Bristol-Myers Squibb)

3. The Global Addiction Market

• 3.1 The Addiction Market in 2007
  • 3.1.1 Leading Addiction Therapy Areas, 2007
  • 3.1.2 Leading Addiction Brands, 2007
  • 3.1.3 Leading Manufacturers of Addiction Drugs, 2007
• 3.2 Global Addiction Market Forecasts, 2008-2023
  • 3.2.1 Addiction Market Forecast, 2008-2023
  • 3.2.2 Addiction Therapy Area Sales Forecast, 2008-2023

4. The Global Smoking Cessation Market

• 4.1 The Smoking Cessation Market in 2007
  • 4.1.1 Leading Smoking Cessation Product Types, 2007
  • 4.1.2 Leading Manufacturers of Smoking Cessation Products, 2007
• 4.2 Smoking Cessation Market Forecasts, 2008-2023
  • 4.2.1 Global Smoking Cessation Market Forecast, 2008-2023
  • 4.2.2 Smoking Cessation Product Type Sales Forecast, 2008-2023
  • 4.2.3 Chantix/Champix Sales Forecast, 2008-2023

5. The Global Obesity Market

• 5.1 The Obesity Market in 2007
  • 5.1.1 Leading Obesity Brands, 2007
  • 5.1.2 Leading Manufacturers of Obesity Drugs, 2007
• 5.2 Obesity Market Forecasts, 2008-2023
  • 5.2.1 Global Obesity Market Forecast, 2008-2023
  • 5.2.2 Xenical Sales Forecast, 2008-2023
  • 5.2.3 Reductil/Meridia Sales Forecast 2008-2023
  • 5.2.4 Alli Sales Forecast, 2008-2023
  • 5.2.5 Acomplia Sales Forecast, 2008-2023

6. The Global Drug Addiction Market

• 6.1 The Drug Addiction Market in 2007
  • 6.1.1 Leading Drug Addiction Product Types, 2007
  • 6.1.2 Leading Manufacturers of Drug Addiction Products, 2007
• 6.2 Drug Addiction Market Forecasts, 2008-2023
  • 6.2.1 Global Drug Addiction Market Forecast, 2008-2023
  • 6.2.2 Drug Addiction Product Type Sales Forecast, 2008-2023
  • 6.2.3 Suboxone/Subutex Sales Forecast, 2008-2023

7. The Global Alcohol Dependency Market

• 7.1 The Alcohol Dependency Market in 2007
  • 7.1.1 Leading Alcohol Dependency Drug Types, 2007
  • 7.1.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
• 7.2 Alcohol Dependency Market Forecasts, 2008-2023
  • 7.2.1 Global Alcohol Dependency Market Forecast, 2008-2023
  • 7.2.2 Alcohol Dependency Drug Type Sales Forecast, 2008-2023
  • 7.2.3 Campral/Aotal Forecast, 2008-2023
  • 7.2.4 Vivitrol Sales Forecast, 2008-2023

8. Leading Addiction Country Markets

• 8.1 Top Twelve Addiction Country Markets, 2007
• 8.2 Addiction Market Country Forecasts, 2008-2023
• 8.3 The US Addiction Market
  • 8.3.1 Prevalence of Addiction in the US
  • 8.3.2 Smoking Cessation Dominated the US Addiction Market in 2007
  • 8.3.3 Forecast for the US Addiction Market, 2008-2023
• 8.4 The UK Addiction Market
  • 8.4.1 Prevalence of Addiction in the UK
  • 8.4.2 There is Greater Reimbursement of Addiction Drugs in the UK Market
  • 8.4.3 Forecast for the UK Addiction Market, 2008-2023
• 8.5 The French Addiction Market
  • 8.5.1 Prevalence of Addiction in France
  • 8.5.2 France has High Revenues in the Drug and Alcohol Addiction Markets
  • 8.5.3 Forecast for the French Addiction Market, 2008-2023

9. SWOT Analysis of the Addiction Market

• 9.1 Analysis of the Market
• 9.2 Strengths of the Addiction Industry
  • 9.2.1 Development of Addiction Vaccines and Novel Drug Formulations
  • 9.2.2 Expansion into New Therapeutic Areas
• 9.3 Weaknesses of the Addiction Therapy Industry
  • 9.3.1 Currently Marketed Addiction Therapies Lack Efficacy
  • 9.3.2 Poor Patient Compliance
• 9.4 Opportunities in the Addiction Market
  • 9.4.1 Addiction is Prevalent Worldwide and Increasing
  • 9.4.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets
  • 9.4.3 Prevalence of Obesity Worldwide and in Major Country Markets
  • 9.4.4 Prevalence of Drug Use Worldwide and in Major Country Markets
  • 9.4.5 Alcohol Consumption and Dependence Worldwide and in Major Country Markets
  • 9.4.6 There is Considerable Under-Treatment of Patients
  • 9.4.7 The Cost of Addiction is High
  • 9.4.8 Awareness of the Costs of Addiction is Increasing
  • 9.4.9 Smoking Legislation is Spreading
• 9.5 Threats to the Addiction Market
  • 9.5.1 Reimbursement is the Key to Success in the Addiction Market
  • 9.5.2 Concern over Side-Effects of Addiction Drugs
  • 9.5.3 Behavioural Therapy is Often Preferred to Treatment with Drugs
  • 9.5.4 Social Stigma and Lack of Education and Resources

10. The Addiction Therapy Pipeline

• 10.1 Some Areas of the Addiction Pipeline are Stronger than Others
• 10.2 The Smoking Cessation Product Pipeline
  • 10.2.1 Addiction Vaccines Will Target Nicotine Dependence
  • 10.2.2 Surinabant (Sanofi-Aventis)
  • 10.2.3 EVT 302 (Evotec)
  • 10.2.4 NicVAX (Nabi Biopharmaceuticals)
  • 10.2.5 NIC002 (Cytos Biotechnology/Novartis)
  • 10.2.6 TA-NIC (Celtic Pharma)
  • 10.2.7 Niccine (Independent Pharmaceutica)
  • 10.3 The Obesity Drug Pipeline
    • 10.3.1 The Obesity Pipeline has had a High Failure Rate
    • 10.3.2 Contrave (Orexigen)
    • 10.3.3 CP-945598/Otenabant (Pfizer)
    • 10.3.4 Lorcaserin (Arena)
    • 10.3.5 Qnexa (Vivant)
    • 10.3.6 ATL-962/Cetilistat (Alizyme/Takeda)
    • 10.3.7 Pramlintide/Metreleptin (Amylin)
    • 10.3.8 Histalean (OBEcure)
    • 10.3.9 Empatic (Orexigen)
    • 10.3.10 Liraglutide (Novo Nordisk)
• 10.4 The Drug Addiction Therapy Pipeline
  • 10.4.1 Cocaine Treatment is the Most Promising Drug Addiction Pipeline Area
  • 10.4.2 Vivitrol (Alkermes)
  • 10.4.3 Probuphine (Titan)
  • 10.4.4 TA-CD (Celtic Pharma)
  • 10.4.5 SYN-117 (Synosia Therapeutics/Roche)
  • 10.4.6 Lobeline (Yaupon Therapeutics)
  • 10.4.7 Naltrexone Implant (Indevus)
  • 10.4.8 Tetrodin (WEX Pharmaceuticals)
  • 10.4.9 XY2401 (Xytis/National Institute on Drug Abuse/Rottapharm)
• 10.5 The Alcohol Dependency Therapy Pipeline
  • 10.5.1 The Alcohol Dependency Pipeline Has Plenty of Room for Novel Products
  • 10.5.2 Nalmefene (Biotie Therapies /Lundbeck/Somaxon): A New Drug for Dependency Disorders
  • 10.5.3 Naltrexone Depot (Elbion NV)
  • 10.5.4 ALKS 29 (Alkermes)
• 10.6 The Pipeline for Other Addiction Therapies

11. Expert Opinion from Key Opinion-Leaders in the Addiction Industry

• 11.1 Dr Raafat Fahim, President and Chief Executive Officer, Nabi Biopharmaceuticals
  • 11.1.1 Vaccines in the Pipeline for Nicotine Addiction
  • 11.1.2 NicVAX
  • 11.1.3 Other Nicotine Vaccines
• 11.2 Industry Representative from the Addiction Therapy Sector
  • 11.2.1 Type of Addictions with Greatest Market Growth Potential
  • 11.2.2 Key Unmet Needs For Alcohol Dependent Patients
  • 11.2.3 Key Advantages of Nalmefene
  • 11.2.4 The Future of the Alcohol Dependency Market

12. Conclusions

• 12.1 The Addiction Market in 2007
• 12.2 Opportunity for Growth in the Addiction Market
• 12.3 Visiongain' s Forecast for the Addiction Market, 2008-2023

• Table 2.1 Global Prevalence of Addiction and Drug Use
• Table 2.2 Key Drugs Prescribed Off-Label for Addiction Therapy
• Table 2.3 Major Johnson & Johnson Nicotine Replacement Therapy Brands
• Table 2.4 Major GSK Nicotine Replacement Therapy Brands
• Table 2.5 Major Novartis Nicotine Replacement Therapy Brands
• Table 3.1 Leading Addiction Therapy Areas, 2007
• Table 3.2 Leading Addiction Brands, 2007
• Table 3.3 Leading Manufacturers of Addiction Drugs, 2007
• Table 3.4 Global Addiction Market Forecast, 2008-2013
• Table 3.5 Global Addiction Market Forecast, 2014-2023
• Table 3.6 Addiction Therapy Area Sales Forecast, 2008-2013
• Table 3.7 Addiction Therapy Area Sales Forecast, 2014-2023
• Table 4.1 Leading Smoking Cessation Product Types, 2007
• Table 4.2 Leading Manufacturers of Smoking Cessation Products, 2007
• Table 4.3 Global Smoking Cessation Market Forecast, 2008-2013
• Table 4.4 Global Smoking Cessation Market Forecast, 2014-2023
• Table 4.5 Smoking Cessation Product Type Sales Forecast, 2008-2013
• Table 4.6 Smoking Cessation Product Type Sales Forecast, 2014-2023
• Table 5.1 Leading Obesity Brands, 2007
• Table 5.2 Leading Manufacturers of Obesity Drugs, 2007
• Table 5.3 Global Obesity Market Forecast, 2008-2013
• Table 5.4 Global Obesity Market Forecast, 2014-2023
• Table 5.5 Obesity Brands Sales Forecasts, 2008-2013
• Table 5.6 Obesity Brands Sales Forecasts, 2014-2023
• Table 6.1 Leading Drug Addiction Product Types, 2007
• Table 6.2 Leading Manufacturers of Drug Addiction Products, 2007
• Table 6.3 Global Drug Addiction Market Forecast, 2008-2013
• Table 6.4 Global Drug Addiction Market Forecast, 2014-2023
• Table 6.5 Drug Addiction Product Type Sales Forecast, 2008-2013
• Table 6.6 Drug Addiction Product Type Sales Forecast, 2014-2023
• Table 6.7 Suboxone/Subutex Sales Forecast, 2008-2013
• Table 6.8 Suboxone/Subutex Sales Forecast, 2014-2023
• Table 7.1 Leading Alcohol Dependency Drug Types, 2007
• Table 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
• Table 7.3 Global Alcohol Dependency Market Forecast, 2008-2013
• Table 7.4 Global Alcohol Dependency Market Forecast, 2014-2023
• Table 7.5 Alcohol Dependency Drug Type Sales Forecast, 2008-2013
• Table 7.6 Alcohol Dependency Drug Type Sales Forecast, 2014-2023
• Table 7.7 Campral/Aotal and Vivitrol Sales Forecast, 2008-2013
• Table 7.8 Campral/Aotal and Vivitrol Sales Forecast, 2014-2023
• Table 8.1 Top Twelve Addiction Country Markets, 2007
• Table 8.2 Addiction Market Country Forecasts, 2008-2013
• Table 8.3 Addiction Market Country Forecasts, 2014-2023
• Table 8.4 Prevalence of Addiction and Drug Use in the US
• Table 8.5 The US Addiction Market, 2007
• Table 8.6 Prevalence of Addiction and Drug Use in the UK
• Table 8.7 The UK Addiction Market, 2007
• Table 8.8 Prevalence of Addiction and Drug Use in France
• Table 8.9 The French Addiction Market, 2007
• Table 9.1 SWOT Chart for Addiction Market
• Table 9.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets
• Table 9.3 Prevalence of Obesity Worldwide and in Major Country Markets
• Table 9.4 Worldwide Drug Use, 2006/07
• Table 9.5 Prevalence of Opioid Drug Use Worldwide and in Major Country Markets
• Table 9.6 Prevalence of Cocaine Use Worldwide and in Major Country
• Table 9.7 Alcohol Consumption & Dependence Worldwide & in Major Country Markets
• Table 10.1 Key Smoking Cessation Pipeline Products
• Table 10.2 Key Obesity Pipeline Drugs
• Table 10.3 Key Drug Addiction Pipeline Therapies
• Table 10.4 Key Alcohol Dependency Pipeline Drugs

List of Figures

• Figure 3.1 Leading Addiction Therapy Areas, 2007
• Figure 3.2 Leading Addiction Brands, 2007
• Figure 3.3 Leading Manufacturers of Addiction Drugs, 2007
• Figure 3.4 Global Addiction Market Forecast, 2008-2023
• Figure 3.5 Addiction Therapy Area Sales Forecast, 2008-2023
• Figure 3.6 Addiction Therapy Area Sales Forecast and Market Share, 2008-2023
• Figure 3.7 Addiction Therapy Area Market Share, 2013
• Figure 3.8 Addiction Therapy Area Market Share, 2018
• Figure 3.9 Addiction Therapy Area Market Share, 2023
• Figure 4.1 Leading Smoking Cessation Product Types, 2007
• Figure 4.2 Leading Manufacturers of Smoking Cessation Products, 2007
• Figure 4.3 Global Smoking Cessation Market Forecast, 2008-2023
• Figure 4.4 Smoking Cessation Product Type Sales Forecast, 2008-2023
• Figure 4.5 Smoking Cessation Product Type Sales Forecast & Market Share, 2008-2023
• Figure 4.6 Chantix/Champix Sales Forecast, 2008-2023
• Figure 5.1 Leading Obesity Brands, 2007
• Figure 5.2 Leading Manufacturers of Obesity Drugs, 2007
• Figure 5.3 Global Obesity Market Forecast, 2008-2023
• Figure 5.4 Xenical Sales Forecast, 2008-2023
• Figure 5.5 Reductil/Meridia Sales Forecast, 2008-2023
• Figure 5.6 Alli Sales Forecast, 2008-2023
• Figure 5.7 Acomplia Sales Forecast, 2008-2023
• Figure 6.1 Leading Drug Addiction Product Types, 2007
• Figure 6.2 Leading Manufacturers of Drug Addiction Products, 2007
• Figure 6.3 Global Drug Addiction Market Forecast, 2008-2023
• Figure 6.4 Drug Addiction Product Type Sales Forecast, 2008-2023
• Figure 6.5 Drug Addiction Product Type Sales Forecast and Market Share, 2008-2023
• Figure 6.6 Suboxone/Subutex Sales Forecast, 2008-2023
• Figure 7.1 Leading Alcohol Dependency Drug Types, 2007
• Figure 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
• Figure 7.3 Global Alcohol Dependency Market Forecast, 2008-2023
• Figure 7.4 Alcohol Dependency Drug Type Sales Forecast, 2008-2023
• Figure 7.5 Alcohol Dependency Drug Type Sales Forecast and Market Share, 2008-2023
• Figure 7.6 Campral/Aotal Sales Forecast, 2008-2023
• Figure 7.7 Vivitrol Sales Forecast, 2008-2023
• Figure 8.1 Leading Addiction Country Markets, 2007
• Figure 8.2 Leading Addiction Country Markets, 2013
• Figure 8.3 Leading Addiction Country Markets, 2018
• Figure 8.4 Leading Addiction Country Markets, 2023
• Figure 8.5 The US Addiction Market, 2007
• Figure 8.6 US Addiction Market Sales Forecast, 2008-2023
• Figure 8.7 The UK Addiction Market, 2007
• Figure 8.8 UK Addiction Market Sales Forecast, 2008-2023
• Figure 8.9 The French Addiction Market, 2007
• Figure 8.10 French Addiction Market Sales Forecast, 2008-2023
• Figure 9.1 Top-Ten Countries for Numbers of Tobacco Users
• Figure 9.2 Prevalence of Obesity in Major Country Markets
• Figure 9.3 Prevalence of Opioid Drug Use in Major Country Markets
• Figure 9.4 Prevalence of Cocaine Use in Major Country Markets
• Figure 9.5 Alcohol Consumption and Dependence in Major Country Markets

Companies Listed

• Abbott Laboratories
• Actavis
• Alizyme
• Alkermes
• Amylin
• Arena
• AstraZeneca
• Barr
• Biotie Therapies (Finland)
• Biovail
• Bristol-Myers Squibb
• Celtic Pharma
• Cephalon
• CV Therapeutics
• Cytos Biotechnology
• Drake University (US)
• Eisai
• Elbion NV
• Eli Lilly
• European Medicines Agency (EMEA)
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Evotec
• Food and Drug Administration (FDA)
• Forest
• GSK
• Independent Pharmaceutica
• Indevus
• Johnson & Johnson
• Karolinska Institutet (Sweden)
• Lundbeck
• Medley (Brazil)
• Merck & Co.
• Merck KGaA
• Nabi Biopharmaceuticals
• National Health Service (NHS, UK)
• National Institute for Health and Clinical Excellence (NICE, UK)
• National Institute on Drug Abuse (NIDA, USA)
• National Institutes of Health (NIH, USA)
• Novartis
• Novo Nordisk
• OBEcure
• Orexigen
• Pfizer
• Reckitt Benckiser
• Roche
• Rottapharm (Italy)
• Sanofi-Aventis
• Schering-Plough
• Solvay
• Somaxon
• Synosia Therapeutics
• Takeda
• Titan
• Vivant
• WEX Pharmaceuticals
• World Health Organization (WHO)
• Xytis
• Yaupon Therapeutics